Advertisement

Novel Medical Therapeutics for Hypertrophic Cardiomyopathy

  • Stephen B. HeitnerEmail author
Chapter

Abstract

Drugs used in the treatment of HCM are largely off-label. In addition, their efficacy is variable, with none approaching a high level of consistent efficacy. Accordingly, increasingly symptomatic patients move on to invasive therapies, including septal reduction therapy and heart transplantation. HCM has been given orphan drug discovery status, spurring multiple companies to invest in novel pharmacotherapies in this space. Three drugs have reached development, with two recently halted. The remaining drug, mavacamten (Myokardia, Inc.), is approaching its pivotal trial after encouraging results in pilot trials on patients with obstructive HCM. Further research is needed, but it seems likely that new medications with greater efficacy will be available commercially within the next decade.

Keywords

Novel drugs Orphan drug Mavacamten Perhexiline Eleclazine 

References

  1. 1.
    Authors/Task Force, m., et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(39):2733–79.CrossRefGoogle Scholar
  2. 2.
    Gersh BJ, et al. 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2011;58(25):e212–60.CrossRefGoogle Scholar
  3. 3.
    Maron MS, et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med. 2003;348(4):295–303.CrossRefGoogle Scholar
  4. 4.
    Fifer MA, Vlahakes GJ. Management of symptoms in hypertrophic cardiomyopathy. Circulation. 2008;117(3):429–39.CrossRefGoogle Scholar
  5. 5.
    Force T, et al. Research priorities in hypertrophic cardiomyopathy: report of a Working Group of the National Heart, Lung, and Blood Institute. Circulation. 2010;122(11):1130–3.CrossRefGoogle Scholar
  6. 6.
    Ashrafian H, Horowitz JD, Frenneaux MP. Perhexiline. Cardiovasc Drug Rev. 2007;25(1):76–97.CrossRefGoogle Scholar
  7. 7.
    Essop MF, Opie LH. Metabolic therapy for heart failure. Eur Heart J. 2004;25(20):1765–8.CrossRefGoogle Scholar
  8. 8.
    Lee L, Horowitz J, Frenneaux M. Metabolic manipulation in ischaemic heart disease, a novel approach to treatment. Eur Heart J. 2004;25(8):634–41.CrossRefGoogle Scholar
  9. 9.
    Song Y, et al. Blocking late sodium current reduces hydrogen peroxide-induced arrhythmogenic activity and contractile dysfunction. J Pharmacol Exp Ther. 2006;318(1):214–22.CrossRefGoogle Scholar
  10. 10.
    Belardinelli L, et al. A novel, potent, and selective inhibitor of cardiac late sodium current suppresses experimental arrhythmias. J Pharmacol Exp Ther. 2013;344(1):23–32.CrossRefGoogle Scholar
  11. 11.
    Coppini R, et al. Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy. Circulation. 2013;127(5):575–84.CrossRefGoogle Scholar
  12. 12.
    Sossalla S, et al. Ranolazine improves diastolic dysfunction in isolated myocardium from failing human hearts--role of late sodium current and intracellular ion accumulation. J Mol Cell Cardiol. 2008;45(1):32–43.CrossRefGoogle Scholar
  13. 13.
    Barry WH, Horowitz JD, Smith TW. Comparison of negative inotropic potency, reversibility, and effects on calcium influx of six calcium channel antagonists in cultured myocardial cells. Br J Pharmacol. 1985;85(1):51–9.CrossRefGoogle Scholar
  14. 14.
    Abozguia K, et al. Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy. Circulation. 2010;122(16):1562–9.CrossRefGoogle Scholar
  15. 15.
    Makielski JC, Farley AL. Na(+) current in human ventricle: implications for sodium loading and homeostasis. J Cardiovasc Electrophysiol. 2006;17(Suppl 1):S15–20.CrossRefGoogle Scholar
  16. 16.
    Olivotto I, et al. Novel approach targeting the complex pathophysiology of hypertrophic cardiomyopathy: the impact of late sodium current inhibition on exercise capacity in subjects with symptomatic hypertrophic cardiomyopathy (LIBERTY-HCM) trial. Circ Heart Fail. 2016;9(3):e002764.CrossRefGoogle Scholar
  17. 17.
    Gentry JL 3rd, et al. Ranolazine for treatment of angina or dyspnea in hypertrophic cardiomyopathy patients (RHYME). J Am Coll Cardiol. 2016;68(16):1815–7.CrossRefGoogle Scholar
  18. 18.
    Green EM, et al. A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice. Science. 2016;351(6273):617–21.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Knight Cardiovascular InstituteOregon Health and Science UniversityPortlandUSA
  2. 2.OHSU Hypertrophic Cardiomyopathy CenterPortlandUSA

Personalised recommendations